Apheresis market growth drivers, and segmentation analysis

Apheresis is a medical process that involves the purification or separation of different blood components. It entails withdrawing blood from a donor or patient via Venipuncture and collecting it in equipment that separates the desired component from the blood. At the end of the procedure, the remaining blood and other components are returned to the donor or patient. The global apheresis market was worth $1.97 billion in 2021 and is expected to be worth $3.87 billion by 2030, displaying a 7.78% CAGR from 2021 to 2030.

According to The American Society for Apheresis, apheresis can be a supportive treatment for over 87 diseases. Furthermore, according to the United States National Library of Medicine, as of January 21, 2021, there are approximately 47 clinical trials related to apheresis for various hematological diseases across the United States National Library of Medicine.

Growth drivers of the apheresis market

Increased global demand for blood components and a rise in government programs to encourage blood donation are the main drivers fuelling the apheresis market‘s expansion. Acute disseminated encephalomyelitis, neonatal cardiac lupus, and autoimmune hemolyticanemia are just a few of the recently approved conditions that can be treated with apheresis. Haemoneticsis, a blood management product company, received FDA (Food and Drug Administration) approval in October 2020 for NexSys PCS with persona technology, which customizes plasma collection based on an individual donor’s body composition. . Furthermore, Kaneka Corporation, a chemical, food, and medical device company launched rheocarna, an adsorption type blood purification device that treats a severe form of arteriosclerosis obliterans, in October 2020. Additionally, the increased use of plasma donation in treating burn patients, trauma patients, and patients suffering from serious disorders or major injuries contributes to the market’s growth. Furthermore, patients admitted due to COVID-19 are given plasma treatment therapy.

Restraints

the high cost of apheresis devices, therapeutic apheresis procedures, and apheresis device installation is expected to suppress market growth. In addition, fewer blood donations using apheresis are expected to challenge the apheresis market due to a lack of awareness.

Opportunity

The rising incidence of chronic diseases, the increase in surgical procedures, and the rising number of accidents or injuries are all making a significant contribution to the market’s expansion.

Segmentation analysis

The apheresis market is divided into product, method, procedure, component, end user, and region categories. 

The market is divided into three categories based on product: devices, disposables and reagents, and software. Based on Technology, it is divided into centrifugation, membrane separation, and selective adsorption. By application, the apheresis market is divided into plasmapheresis, plateletpheresis, leukapheresis, and erythropoiesis. End users include blood collection centers. The market is divided into four regions: North America, Europe, Asia-Pacific, Latin America, and the Caribbean.

• According to product, disposables and reagents had the highest income in 2020, and this trend is anticipated to last the entire forecasted time. Additionally, the category of centrifugal apheresis devices is anticipated to grow at the quickest CAGR throughout the anticipated period. Due to the benefits of centrifugation over other techniques and its effectiveness in separating all types of blood components, the market for centrifugal apheresis machines is expanding.
• According to Technology, the centrifugation method held the biggest market share and is anticipated to do so for the foreseeable future. This is because blood components like packed red blood cells (PRBCs) and fresh frozen plasma are frequently prepared using intense spinning and centrifugation (FFP).
• According to the Application, Plasmapheresis held the greatest market share in 2020, representing nearly 50% of the entire market. Grifols developed plasmapheresis in 1951 to separate plasma from blood cells. The primary growth drivers for the market are the increasing prevalence of blood-related diseases and the rising need for medicines generated from plasma.
• According to End-Users, the blood component suppliers and collection centers held 67.5 percent of the global market in 2020. It is because there are more blood centers, more instruments for testing blood components, and more people are aware of blood collection facilities.
• North America regulates the largest share of the market. The rising prevalence of blood-related diseases such as kidney disease, cancer, and neurological disorders, the presence of developed healthcare infrastructure, and high patient awareness levels are the major drivers driving market growth in North America. According to a 2019 study by the Centers for Disease Control and Prevention (CDC), chronic kidney disease affects approximately 37 million (15%) people in the United States (CKD). Furthermore, the Europe apheresis equipment market is expected to grow at a CAGR of around 6.39% between 2020 and 2028.

Major players 

Key market players in the apheresis market are:

• Kawasumi
• Asahi Kasei Medical
• Kaneka Corporation
• Nikkiso
• HemaCare Corporation
• B. Braun Melsungen AG
• others